Breaking News

BioCentriq’s $29.2M in Funding to Enhance Cell Therapy Services

Will further accelerate capabilities to provide end-to-end services for cell therapy development and manufacturing.

BioCentriq, a global cell-based therapy contract development and manufacturing organization (CDMO), reported the successful completion of its latest round of fundraising, securing $29.2 million to accelerate delivery of cell therapies by translating, optimizing, and scaling processes for GMP manufacture. With this capital, BioCentriq will further accelerate its capabilities to provide end-to-end services for cell therapy development and manufacturing. The funds will be used to enhance BioCent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters